-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OruDhIcdzAnArWgG+1qi2f1IhR2xnoIRoK3d6gsZAA9LNg4X/0e+nJPt3oVWRMBh Kt+XkgkbiXUVbizgJ98MUw== 0001193125-07-114408.txt : 20070515 0001193125-07-114408.hdr.sgml : 20070515 20070515061430 ACCESSION NUMBER: 0001193125-07-114408 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070515 ITEM INFORMATION: Other Events FILED AS OF DATE: 20070515 DATE AS OF CHANGE: 20070515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12477 FILM NUMBER: 07849247 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: 805-447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 27-3-C CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 15, 2007

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

Delaware    000-12477    95-3540776

(State or Other Jurisdiction

of Incorporation)

   

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One Amgen Center Drive

Thousand Oaks, CA

         91320-1799     
(Address of principal executive offices)       (Zip Code)   

Registrant’s telephone number, including area code

805-447-1000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events

Amgen Inc. intends to draw down on our commercial paper program and utilize the proceeds to repurchase our common stock, par value $.0001 per share, pursuant to our stock repurchase programs authorized by the Board of Directors. Also, we are currently reviewing additional borrowing opportunities to fully fund stock repurchases authorized under our stock repurchase programs this year. As of May 14, 2007, we had approximately $5 billion authorized for stock repurchases under our stock repurchase programs and $1.2 billion available under our commercial paper program.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AMGEN INC.
Date: May 15, 2007     By:   /s/    David J. Scott          
    Name:   David J. Scott
    Title:   Senior Vice President, General Counsel and Secretary

 

3

-----END PRIVACY-ENHANCED MESSAGE-----